| 1 |
Dr. Srinivas K G |
A Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) |
Phase 3 |
D967UC00001 |
“HER2-positive Metastatic Breast Cancer” |
Ongoing |
“Dr. Lavanya S U Clincal Research Coordinator
Ph no: 8296048276”
|
| 2 |
Dr. Srinivas K G |
A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) |
Phase 3 |
D9106C00001 |
Lung Cancer |
Ongoing |
“Dr. Lavanya S U
Clincal Research Coordinator
Ph no: 8296048276”
|
| 3 |
Dr. Srinivas K G |
A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) |
Phase 3 |
D3614C00001 |
Triple Negative Breast Cancer |
Ongoing |
“Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276” |
| 4 |
Dr. Srinivas K G |
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer. (NILE) |
Phase 3 |
D933SC00001 |
Urothelial Cancer |
close out will be done soon |
“Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276” |
| 5 |
Dr. Srinivas K G |
“A randomised, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of DRL_RI with MabThera® in subjects with previously untreated, Stage II-IV, CD20-positive, low tumour burden follicular lymphoma” |
Phase 3 |
RI-01-006 |
Follicular Lymphoma |
Ongoing |
“Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276” |
| 6 |
Dr. Srinivas K G |
A Phase Ib/III Study of Capivasertib Plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) |
Phase 3 |
D3614DC00001 |
“(HR+/HER2-) Metastatic Breast Cancer” |
Waiting for site Initiation |
“Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276” |
| 7 |
Dr. Vishwjeeth K Pai |
Multiomics approach to identify early detection biomarkers – A multi cancer effort in India, (Version No. 01, dated 22nd March, 2022) |
NA |
“Breast, cervix, colorectal, esophagus, lung, oral, stomach and ovary” |
Waiting for site Initiation |
“Dr. Lavanya S U Clincal Research Coordinator Ph no: 8296048276” |
